BioPharma Credit (LSE:BPCR) Money Market Investments : $0.0 Mil (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Money Market Investments?

BioPharma Credit's money market investment for the quarter that ended in Dec. 2022 was $0.0 Mil. It means BioPharma Credit paid $0.0 Mil to invest on the money market.

Compared with last quarter ($0.0 Mil in Jun. 2022 ), BioPharma Credit paid the same money to invest on the money market in Dec. 2022 ($0.0 Mil).

BioPharma Credit Money Market Investments Historical Data

The historical data trend for BioPharma Credit's Money Market Investments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Money Market Investments Chart

BioPharma Credit Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Money Market Investments

Get a 7-Day Free Trial

48.85

BioPharma Credit Semi-Annual Data
	Jun17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Dec23
Money Market Investments	Get a 7-Day Free Trial							-	-	-	-	48.85

BioPharma Credit Money Market Investments Calculation

Money Market Investments carried on banks' balance sheet.

BioPharma Credit (LSE:BPCR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Money Market Investments

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ

Website

https://www.bpcruk.com

BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines